How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

982 results for

Endocrine Manifestations of HIV

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

841. Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease. Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus. Uncontrolled abnormal thyroid function. Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease. Hemoglobin levels < 7.5 g/dL. History of sclerosing cholangitis, cirrhosis, or hepatic impairment. Renal disease manifested by > 2.0mg/dL serum creatinine. History of avascular hip necrosis, active tuberculosis, ocular (...) herpes simplex or ocular varicella zoster, malignant disease, and HIV or hepatitis B or C. Adrenal insufficiency. Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or abscess. History of uncontrolled psychiatric disorders or seizure disorders. History of asthma requiring ongoing use of inhaled steroids. Recent history of drug or alcohol abuse. Positive stool test for bacterial pathogens, C diff or O&P. Vaccination within 28 days prior to Randomization. Allergies

2009 Clinical Trials

842. Smoking Cessation and Sexual Health in Men

cord damage. Clinically significant untreated renal or endocrine disease. Uncontrolled hypotension or hypertension manifested by systolic blood pressure >170 or <90 mm Hg or diastolic blood pressure >100 or <50 mm Hg. History of serious drug abuse or serious alcohol abuse within the past 12 months (>= 16 points on the Alcohol Use Disorders Identification Test (AUDIT) and >= 6 on the Drug Abuse Screening Test (DAST-10). Evidence of schizophrenia, bipolar disorder, delusional disorder, or psychotic (...) the past 30 days) Committed to quit smoking Exclusion Criteria: History of HIV infection or active, untreated pelvic or urinary tract infection including, sexually transmitted diseases such as chlamydia genital herpes, gonorrhea, or syphilis. Major pelvic surgery that may have caused nerve damage, or serious bladder, rectal, or abdominal surgery. Neurological impairment due to diabetes, stroke, pelvic nerve damage secondary to trauma, cancer treatments, myasthenia gravis, multiple sclerosis or spinal

2009 Clinical Trials

843. A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

metabolic, hematological, pulmonary, ischemic, or unstable heart disease, gastrointestinal, neurological, psychiatric, renal, urological, endocrine, opthalmologic, or immune mediated disease including HIV or HBsAg positivity Chronic genital herpes Patients who received cytotoxic or immunosuppressive drug therapy within 3 months prior to study participation Previous vaccinations against Herpes Zoster Patients with > 50% of vesicles crusted at screen Patients who received topical or systemic antiviral (...) Description Go to Brief Summary: The purpose of this study is to determine the pharmacokinetics and dosage of EPB-348 that best balances safety and efficacy among adult immunocompetent patients with an acute episode of herpes zoster. Condition or disease Intervention/treatment Phase Herpes Zoster Drug: EPB-348 Drug: Valacyclovir Phase 2 Detailed Description: In cells infected with varicella-zoster virus, there is evidence to suggest that EPB-348 could offer clinically important advantages in the treatment

2009 Clinical Trials

844. Cognitive Behavioral Therapy for Diabetic Neuropathic Pain

MeSH terms: Layout table for MeSH terms Neuralgia Diabetic Neuropathies Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Pain Neurologic Manifestations Signs and Symptoms Diabetes Complications Diabetes Mellitus Endocrine System Diseases (...) of good control which can be expected to resolve spontaneously Confirmation of the study neurologists that pain is not attributable to other medical conditions that could mimic DPNP (e.g., HIV, Hepatitis C, cryoglobulinemia, pernicious anemia, untreated hypothyroidism) Documentation of treatment of neuropathic pain with the maximum dose of one of the medications identified as a first line or second line treatment in either VA guidelines28 or other published consensus recommendations27 with maximum

2009 Clinical Trials

845. A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

Nervous System Diseases Neuralgia Carpal Tunnel Syndrome Diabetic Neuropathies Complex Regional Pain Syndromes Reflex Sympathetic Dystrophy Neuralgia, Postherpetic Disease Pathologic Processes Neuromuscular Diseases Nervous System Diseases Pain Neurologic Manifestations Signs and Symptoms Median Neuropathy Mononeuropathies Nerve Compression Syndromes Cumulative Trauma Disorders Sprains and Strains Wounds and Injuries Diabetes Complications Diabetes Mellitus Endocrine System Diseases Autonomic Nervous (...) syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a Phase IV clinical trial to assess the comparative efficacy and safety of Lidoderm monotherapy versus gabapentin monotherapy in treating a diverse group of peripheral neuropathic pain patients. Condition or disease Intervention/treatment Phase Postherpetic Neuralgia Diabetic Neuropathy Complex Regional Pain Syndrome Carpal Tunnel Syndrome HIV Neuropathy Idiopathic

2009 Clinical Trials

846. Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

. Taking opiates for abdominal pain. History of HIV infection. History of Hepatitis B or C currently exhibiting symptoms expected to worsen during course of study. Requires dialysis or has severely impaired renal function. Severe impairment of liver function. Uncontrolled hypo- or hyperthyroidism. History of adrenal insufficiency. Pregnant or is breast-feeding. Allergic to or intolerant of wheat, egg, soy or milk products. Patient requires a gluten-free diet. Any other medical condition or social (...) table for additonal information Responsible Party: Tranzyme, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: TZP-102-CL-G002 First Posted: April 29, 2009 Last Update Posted: December 11, 2012 Last Verified: December 2012 Keywords provided by Tranzyme, Inc.: gastroparesis diabetes mellitus delayed gastric emptying Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Gastroparesis Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Stomach

2009 Clinical Trials

847. VA106483 and Alpha Blocker Interaction Study in Elderly Males

concomitant medication known to be a cytochrome 3A4 inhibitor Not taking any prescribed or over the counter medications unless agreed with the Investigator and Sponsor No evidence of serious pathology or disease including poorly controlled endocrine disorders; active liver or biliary disease or severe kidney problems; syndrome of inappropriate antidiuretic hormone secretion No history of orthostatic hypotension or syncope. No known hypersensitivity to the IMP or alpha blocker, including severe lactose (...) intolerance. No history of drug or alcohol abuse Negative for HIV, hepatitis B or C Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00879216 Locations Layout table for location information United Kingdom Charles River Clinical Services Edinburgh, United

2009 Clinical Trials

848. A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

participation in the study; The participant had tested positive for the human immunodeficiency virus (HIV) antibody, Hepatitis C antibody, or Hepatitis B surface antigen; The participant had received an investigational product within 30 days prior to randomization; The participant was pregnant or lactating. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information (...) by lysosomal accumulation of glucosylceramide due to impaired glucosylceramide hydrolysis. Type 1 Gaucher disease, the most common form accounts for greater than (>) 90% of cases and does not involve the central nervous system (CNS). Typical manifestations of Type 1 Gaucher disease include splenomegaly, hepatomegaly, thrombocytopenia, anemia, skeletal pathology and decreased quality of life. The disease manifestations are caused by the accumulations of glucosylceramide (storage material) in Gaucher cells

2009 Clinical Trials

849. A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)

history of hepatitis B or C or HIV infection Patient has skin-condition that may decrease sensitivity in area of neuropathic pain Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00837941 Sponsors and Collaborators Merck Sharp & Dohme Corp (...) . Investigators Layout table for investigator information Study Director: Medical Monitor Merck Sharp & Dohme Corp. More Information Go to Layout table for additonal information Responsible Party: Merck Sharp & Dohme Corp. ClinicalTrials.gov Identifier: Other Study ID Numbers: 0000-115 2009_515 First Posted: February 6, 2009 Last Update Posted: July 27, 2015 Last Verified: July 2015 Additional relevant MeSH terms: Layout table for MeSH terms Pain Diabetic Neuropathies Neurologic Manifestations Signs

2009 Clinical Trials

850. A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects

< 60 mmHg or > 90 mmHg at screening. Resting heart rate is outside the range of 45 to 100 bpm. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody. A positive test for HIV antibody. A fasting triglyceride level >400mg/dL (4.45mmol/L). Anemia defined by hemoglobin concentration <11.0g/dL for males or <10.0g/lL for females. Significant renal disease as manifested by one or more of the following: Creatinine clearance <80 mL/min. (estimated from serum creatinine (SCr (...) terms Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Glucagon Glucagon-Like Peptide 1 Gastrointestinal Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Incretins

2009 Clinical Trials

851. A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

had any clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal (GI), pulmonary, neurologic, endocrine, metabolic (e.g. hypokalemia, hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may confound the study results or, in the opinion of the Investigator, may preclude participation in the study The participant had tested positive for the human immunodeficiency virus (HIV) antibody (...) nervous system (CNS). Typical manifestations of Gaucher disease type 1 include splenomegaly, hepatomegaly, thrombocytopenia, anemia, bone disease, and decreased quality of life. The disease manifestations are caused by the accumulation of glucosylceramide (storage material) in macrophages (called Gaucher cells) which have infiltrated the spleen and liver as well as other tissues. Eliglustat tartrate is a small molecule drug developed as an oral therapy which acts to specifically inhibit production

2009 Clinical Trials

852. A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Keywords provided by AbbVie ( AbbVie (prior sponsor, Abbott) ): CKD Stages 3&4 Endothelin antagonist Proteinuria Additional relevant MeSH terms: Layout table for MeSH terms Kidney Diseases Renal Insufficiency, Chronic Diabetic Nephropathies Albuminuria Urologic Diseases Renal Insufficiency Diabetes Complications Diabetes Mellitus Endocrine System Diseases Proteinuria Urination Disorders Urological Manifestations Signs and Symptoms Pharmaceutical Solutions Atrasentan Antineoplastic Agents Endothelin (...) stenosis; or Coronary revascularization procedure. 16.Subject has a history of viral or bacterial infection within 4 weeks of Screening or HIV infection. 17.Subject has scheduled or planned surgery with general anesthesia within 12 weeks of Screening Visit. 18.Subject has a history of drug or alcohol abuse within 6 months prior to the Screening Visit. 19.Subject has evidence of poor compliance with diet or medication that may interfere, in the Investigator's opinion, with adherence to the protocol. 20

2009 Clinical Trials

853. N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

on medications Other secondary forms of hypertension (endocrine, renovascular) History of intolerance to: Both ACE-I and ARBs; The investigational supplements; Iodinated radiologic contrast material. Known non diabetic renal disease, or history of solid organ transplantation. Hepatitis virus or Human Immunodeficiency virus infections Use of one of the following medications within 2 months prior to enrollment in the study: Metformin. Thiazolidinediones (pioglitazone or rosiglitazone); Prescription-grade (...) Supplements Complementary Therapies Additional relevant MeSH terms: Layout table for MeSH terms Kidney Diseases Diabetic Nephropathies Proteinuria Urologic Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Urination Disorders Urological Manifestations Signs and Symptoms Acetylcysteine N-monoacetylcystine Silybin Antiviral Agents Anti-Infective Agents Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action

2009 Clinical Trials

854. Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

and cotinine) at Screening and Check-in (Day -1). Participant had clinical chemistry, hematology, and complete urinalysis (fasted for at least 8 hours) results within the reference range for the testing laboratory (except results associated with T2DM) unless the out-of-range results were deemed not clinically meaningful by the investigator or sponsor. Participant had a negative test result for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV), and no known history of human (...) immunodeficiency virus. Exclusion Criteria: Participant was currently participating in another investigational study or took an investigational drug within 30 days prior to Day 1. Participant received alogliptin previously. Participant was a study site employee, or was an immediate family member (ie, spouse, parent, child, or sibling) of a study site employee involved in conduct of this study. Participant received or donated blood or blood products within 30 days prior to Screening or planned to donate blood

2009 Clinical Trials

855. VA106483 Dose Response Study in Elderly Males

be within normal range) Willing and able to participate and provides written informed consent Exclusion Criteria: Cardiac insufficiency; signs or symptoms suggestive of heart failure or requiring treatment with diuretics Supine arterial blood pressure higher than 170/100 mmHg or less than 105/60 mm Hg Presence of poorly controlled endocrine disorders Renal insufficiency, active hepatic and/or biliary disease Hyponatraemia. Serum sodium level must be within normal limits Syndrome of inappropriate (...) antidiuretic hormone (ADH) secretion Symptoms suggestive of psychogenic or habitual polydipsia or of diabetes insipidus Known hypersensitivity to the IP or any constituent of the IP Use of any non-prescription preparation within 72 hours prior to study entry, with the exception of defined pain killers A history of alcohol abuse or drug addiction within the last 2 years Positive screen for HIV, hepatitis B or C Currently taking any diuretics or any concomitant medication known to be a cytochrome 3A4

2009 Clinical Trials

856. Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

or alcohol abuse within the past 2 years Creatinine clearance < 50 mL/min at the Screening visit Malignancy other than basal cell carcinoma and carcinoma in situ within the past 2 years History of chronic hepatitis B or C, hepatitis within the past 3 months before the Screening visit, or any history of human immunodeficiency virus (HIV) infection Clinically significant hepatic, respiratory, hematological, cardiovascular, renal, or neurological disease, with the exception of diabetic peripheral neuropathy (...) Diseases Pain Neurologic Manifestations Signs and Symptoms Diabetes Complications Diabetes Mellitus Endocrine System Diseases

2009 Clinical Trials

857. Nutritional and Contractile Regulation of Muscle Growth

sessions of moderate to high intensity aerobic or resistance exercise Significant heart, liver, kidney, blood, or respiratory disease Peripheral vascular disease Diabetes mellitus or other untreated endocrine disease Active cancer History of cancer for participants who may be randomly assigned to rapamycin) Acute infectious disease or history of chronic infections (e.g., tuberculosis, hepatitis, HIV, herpes) Treatment with anabolic steroids or corticosteroids within 6 months of study entry Alcohol (...) : Blood flow restriction cuff Phase 1 Detailed Description: Skeletal muscle comprises about 40% of one's body weight and contains about 50% to 75% of all the proteins in the human body. The turnover of protein is a regular process in the human body. In healthy adults, the interplay between muscle protein synthesis and muscle protein breakdown results in no net growth or loss of muscle mass. But when the scale tips towards muscle protein breakdown, muscle wasting can occur. This can result in negative

2009 Clinical Trials

858. Statement on persistent diarrhea in the returned traveller

is strongest for Strongyloides stercoralis, Capillaria philippinensis, Trichuris trichiura, and Schistosoma sp . . Other intestinal flukes (e.g., Fasciolopsis buski ) may also be associated with diarrhea. Viruses Persistent diarrhea is a relatively common manifestation of advanced immunosuppression with HIV, and cytomegalovirus may cause colitis in this setting. Viruses are otherwise not recognized as causes of chronic diarrhea. Non-infectious post-infective functional bowel disorders A change in bowel (...) be advocated for acute traveller's diarrhea (TD). However, even when empiric therapy is initiated, medical assistance should be sought for investigation and management as soon as possible when the patient is very ill (e.g., high fever, prostration, severe abdominal pain), has a significant underlying medical illness, is immunodeficient, or has bloody stools. In practice, the majority of diarrheal episodes resolve, even without treatment, after a period of between hours and weeks. However, noticeable

2006 CPG Infobase

859. Coartem (artemether/lumefantrine)

renal or hepatic impairment to allow for dosing recommendations to be made in these populations. --------------------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------------------- /s (...) . --------------------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------------------- /s/ --------------------- Ozlem Belen 11/25/2008 06:14:33 PM MEDICAL OFFICER Joette Meyer 11/25/2008 07:28:55 PM MEDICAL OFFICER CLINICAL REVIEW Application Type NDA Submission Number 22-268 Submission Code 000 Letter Date June 27, 2008 Stamp Date June 27, 2008

2008 FDA - Drug Approval Package

860. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

8.4.1.2. Rheumatic disease . . 782 8.4.1.3. Endocarditis 782 8.4.2. In?ltrative cardiomyopathies . 783 8.4.2.1. Sarcoidosis 783 8.4.2.2. Amyloidosis 783 8.4.2.3. Fabry disease 783 8.4.2.4. Hemochromatosis 783 8.4.3. Endocrine disorders and diabetes 783 8.4.3.1. Introduction. 783 8.4.3.2. Thyroid disorders 784 8.4.3.3. Pheochromocytoma 784 8.4.3.4. Acromegaly . 784 8.4.3.5. Primary aldosteronism, addison disease, hyperparathyroidism, and hypoparathyroidism . . . . . . 784 8.4.3.6. Diabetes 784 8.4.4 (...) Advanced Cardiac Life Support Subcommittee. The committee conducted comprehensive searching of the scienti?c and medical literature on ventricular arrhythmias and sudden cardiac death (SCD). Literature searching was limited to publications on humans and in English from 1990 to 2006. The search parameters were extended for selected topics when a historical reference was needed or if limited studies existed in English. In addition to broad-based search- ing on ventricular arrhythmias and SCD, speci?c

2006 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>